We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 7 maart 2018

Leukemia - Table of Contents alert Volume 32 Issue 3

If you are unable to see the message below, click here to view.

Volume 32, Issue 3 (March 2018)

In this issue
Original Articles
Letters to the Editor
Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed

Original Articles

Acute myeloid leukemia

Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion

B Kumar, M Garcia, L Weng, X Jung, J L Murakami et al.

Leukemia 2017 32 :575 - 587; August 17, 2017; 10.1038/leu.2017.259


Abstract | Full Text

Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner

P Peña-Martínez, M Eriksson, R Ramakrishnan, M Chapellier, C Högberg et al.

Leukemia 2017 32 :588 - 596; August 18, 2017; 10.1038/leu.2017.261


Abstract | Full Text

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia

M-A Hospital, A Jacquel, F Mazed, E Saland, C Larrue et al.

Leukemia 2017 32 :597 - 605; September 15, 2017; 10.1038/leu.2017.284


Abstract | Full Text

Acute lymphoblastic leukemia

Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia

N Toft, H Birgens, J Abrahamsson, L Griškevicius, H Hallböök et al.

Leukemia 2017 32 :606 - 615; August 18, 2017; 10.1038/leu.2017.265


Abstract | Full Text

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia

S Takao, W Chien, V Madan, D-C Lin, L-W Ding et al.

Leukemia 2017 32 :616 - 625; September 14, 2017; 10.1038/leu.2017.281


Abstract | Full Text

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG

T Sakura, F Hayakawa, I Sugiura, T Murayama, K Imai et al.

Leukemia 2017 32 :626 - 632; September 15, 2017; 10.1038/leu.2017.283


Abstract | Full Text

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL

C Prieto, B López-Millán, H Roca-Ho, R W Stam, D Romero-Moya et al.

Leukemia 2017 32 :633 - 644; September 25, 2017; 10.1038/leu.2017.294


Abstract | Full Text

Chronic lymphocytic leukemia

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

F Nadeu, G Clot, J Delgado, D Martín-García, T Baumann et al.

Leukemia 2017 32 :645 - 653; September 19, 2017; 10.1038/leu.2017.291


Abstract | Full Text

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-?B pathways

D Benedetti, E Tissino, F Pozzo, T Bittolo, C Caldana et al.

Leukemia 2017 32 :654 - 662; September 22, 2017; 10.1038/leu.2017.296


Abstract | Full Text


Targeting nucleolin for better survival in diffuse large B-cell lymphoma

N Jain, H Zhu, T Khashab, Q Ye, B George et al.

Leukemia 2017 32 :663 - 674; July 10, 2017; 10.1038/leu.2017.215


Abstract | Full Text

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

K Karube, A Enjuanes, I Dlouhy, P Jares, D Martin-Garcia et al.

Leukemia 2017 32 :675 - 684; August 14, 2017; 10.1038/leu.2017.251


Abstract | Full Text

Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing

A Zamò, J Pischimarov, M Schlesner, P Rosenstiel, R Bomben et al.

Leukemia 2017 32 :685 - 693; August 21, 2017; 10.1038/leu.2017.270


Abstract | Full Text

Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma

M Fujisawa, M Sakata-Yanagimoto, S Nishizawa, D Komori, P Gershon et al.

Leukemia 2017 32 :694 - 702; August 23, 2017; 10.1038/leu.2017.273


Abstract | Full Text

HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma

Y J Jia, Z B Liu, W G Wang, C B Sun, P Wei et al.

Leukemia 2017 32 :703 - 711; September 28, 2017; 10.1038/leu.2017.299


Abstract | Full Text

Multiple myeloma, gammopathies

Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

R Chakraborty, E Muchtar, S K Kumar, F K Buadi, D Dingli et al.

Leukemia 2017 32 :712 - 718; August 14, 2017; 10.1038/leu.2017.256


Abstract | Full Text

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

S Ailawadhi, J R Mikhael, B R LaPlant, K M Laumann, S Kumar et al.

Leukemia 2017 32 :719 - 728; September 01, 2017; 10.1038/leu.2017.258


Abstract | Full Text

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

S Sidana, N Tandon, A Dispenzieri, M A Gertz, F K Buadi et al.

Leukemia 2017 32 :729 - 735; September 18, 2017; 10.1038/leu.2017.286


Abstract | Full Text

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma

A G Solimando, A Brandl, K Mattenheimer, C Graf, M Ritz et al.

Leukemia 2017 32 :736 - 743; September 28, 2017; 10.1038/leu.2017.287


Abstract | Full Text

14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors

Y Gu, K Xu, C Torre, M Samur, B G Barwick et al.

Leukemia 2017 32 :744 - 751; September 19, 2017; 10.1038/leu.2017.288


Abstract | Full Text

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

J Bae, T Hideshima, G L Zhang, J Zhou, D B Keskin et al.

Leukemia 2017 32 :752 - 764; November 01, 2017; 10.1038/leu.2017.316


Abstract | Full Text

Stem cell transplantation

Extracellular vesicles as potential biomarkers of acute graft-vs-host disease

G Lia, L Brunello, S Bruno, A Carpanetto, P Omedè et al.

Leukemia 2017 32 :765 - 773; August 30, 2017; 10.1038/leu.2017.277


Abstract | Full Text

Molecular targets for therapy

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

E I Andersson, S Pützer, B Yadav, O Dufva, S Khan et al.

Leukemia 2017 32 :774 - 787; August 14, 2017; 10.1038/leu.2017.252


Abstract | Full Text

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

S Degryse, C E de Bock, S Demeyer, I Govaerts, S Bornschein et al.

Leukemia 2017 32 :788 - 800; August 30, 2017; 10.1038/leu.2017.276


Abstract | Full Text


Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells

Y Lai, J Weng, X Wei, L Qin, P Lai et al.

Leukemia 2017 32 :801 - 808; August 03, 2017; 10.1038/leu.2017.249


Abstract | Full Text

Transcriptional control and signal transduction, cell cycle

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling

T Girardi, S Vereecke, S O Sulima, Y Khan, L Fancello et al.

Leukemia 2017 32 :809 - 819; July 24, 2017; 10.1038/leu.2017.225


Abstract | Full Text

Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis

S Gerboth, E Frittoli, A Palamidessi, F C Baltanas, M Salek et al.

Leukemia 2017 32 :820 - 827; August 18, 2017; 10.1038/leu.2017.267


Abstract | Full Text

C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation

A E Marneth, K H M Prange, A S A Al Hinai, S M Bergevoet, N Tesi et al.

Leukemia 2017 32 :828 - 836; September 05, 2017; 10.1038/leu.2017.280


Abstract | Full Text

Letters to the Editor

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis

A Tefferi, T L Lasho, C Finke, N Gangat, C A Hanson et al.

Leukemia 2017 32 :837 - 839; November 01, 2017; 10.1038/leu.2017.318


Abstract | Full Text

A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia

H Sakai, N Hosono, H Nakazawa, B Przychodzen, C Polprasert et al.

Leukemia 2017 32 :839 - 843; November 03, 2017; 10.1038/leu.2017.319


Abstract | Full Text

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

A Ray, D S Das, Y Song, T Hideshima, Y-T Tai et al.

Leukemia 2017 32 :843 - 846; November 06, 2017; 10.1038/leu.2017.322


Abstract | Full Text

Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia

S C Nimmagadda, S Frey, B Edelmann, C Hellmich, L Zaitseva et al.

Leukemia 2017 32 :846 - 849; November 07, 2017; 10.1038/leu.2017.324


Abstract | Full Text

Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53

S Chen, R Gao, C Yao, M Kobayashi, S Z Liu et al.

Leukemia 2017 32 :850 - 854; November 16, 2017; 10.1038/leu.2017.325


Abstract | Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature